IUPAC/Chemical Name
1,3-Propanediamine, N-(2,3-dihydro-1-methoxy-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-
InChi Key
QQGGXAOUSKREAE-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H32N2O/c1-4-24(5-2)16-11-17-25(20-13-7-6-8-14-20)22-18-19-12-9-10-15-21(19)23(22)26-3/h6-10,12-15,22-23H,4-5,11,16-18H2,1-3H3
SMILES Code
CCN(CC)CCCN(C1C(OC)C2=C(C=CC=C2)C1)C3=CC=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
352.52
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Staessen J, Kesteloot H. Moxaprindine in the acute treatment of ventricular arrhythmias in patients with cardiovascular disease. Eur J Clin Pharmacol. 1981 Feb;19(3):167-72. doi: 10.1007/BF00561943. PMID: 7215413.
2: Teirlynck O, Belpaire FM, Andreasen F. Binding of aprindine and moxaprindine to human serum, alpha 1-acid glycoprotein and serum of healthy and diseased humans. Eur J Clin Pharmacol. 1982;21(5):427-31. doi: 10.1007/BF00542331. PMID: 7075647.
3: de Suray JM, Lavis A, Breekpot F. Pharmacokinetic study of aprindine and moxaprindine in dogs. Int J Clin Pharmacol Ther Toxicol. 1981 May;19(5):209-15. PMID: 7251236.
4: Kesteloot H, van de Werf F, Marchandise B, Sluyts R. Influence of moxaprindine treatment on ventricular arrhythmias occurring during maximal exercise stress testing. Acta Cardiol. 1979;34(5):301-9. PMID: 317204.
5: Waleffe A, Guillaume D, Mary-Rabine L, Kulbertus H. The efficacy of intravenous moxaprindine on ventricular ectopic activity. Acta Cardiol. 1980;35(4):257-68. PMID: 6971032.
6: Stryckmans PA, Ronge-Collard E, Delforge A, Lambert M, Suciu S. Effect of 2 anti-arrhythmic drugs aprindine and moxaprindine on the replication capacity of murine and human haemopoietic cells. Scand J Haematol. 1982 Oct;29(4):331-7. doi: 10.1111/j.1600-0609.1982.tb00603.x. PMID: 7178839.
7: Waleffe A, Mary-Rabine L, Kulbertus HE. Study of moxaprindine with programmed electrical stimulation of the heart in patients with reentrant tachyarrhythmias. Am J Cardiol. 1980 Mar;45(3):640-7. doi: 10.1016/s0002-9149(80)80017-8. PMID: 7355761.
